HANDOK Inc. (002390.KS)
KRW 12270.0
(-2.54%)
KRW 12270.0
(-2.54%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 283.45 Billion KRW | 8.42% |
| 2022 | 261.44 Billion KRW | 14.69% |
| 2021 | 227.95 Billion KRW | 8.4% |
| 2020 | 210.29 Billion KRW | 6.58% |
| 2019 | 197.31 Billion KRW | 56.69% |
| 2018 | 125.92 Billion KRW | -18.33% |
| 2017 | 154.19 Billion KRW | -1.01% |
| 2016 | 155.77 Billion KRW | 88.91% |
| 2015 | 82.45 Billion KRW | -0.15% |
| 2014 | 82.58 Billion KRW | 51.64% |
| 2013 | 54.45 Billion KRW | 32.38% |
| 2012 | 41.13 Billion KRW | 3055.27% |
| 2011 | -1.39 Billion KRW | -109.24% |
| 2010 | 15.06 Billion KRW | 25.72% |
| 2009 | 11.98 Billion KRW | -28.81% |
| 2008 | 16.83 Billion KRW | 192.17% |
| 2007 | -18.26 Billion KRW | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 303.08 Billion KRW | 6.92% |
| 2024 Q2 | 316.84 Billion KRW | 4.54% |
| 2023 Q4 | 283.45 Billion KRW | 3.15% |
| 2023 Q1 | 244.24 Billion KRW | -6.58% |
| 2023 Q3 | 274.8 Billion KRW | 0.82% |
| 2023 Q2 | 272.55 Billion KRW | 11.59% |
| 2023 FY | 283.45 Billion KRW | 8.42% |
| 2022 Q1 | 221.75 Billion KRW | -2.72% |
| 2022 Q2 | 245.63 Billion KRW | 10.77% |
| 2022 FY | 261.44 Billion KRW | 14.69% |
| 2022 Q4 | 261.44 Billion KRW | -3.43% |
| 2022 Q3 | 270.71 Billion KRW | 10.21% |
| 2021 Q2 | 206.55 Billion KRW | -6.84% |
| 2021 Q3 | 229.4 Billion KRW | 11.06% |
| 2021 FY | 227.95 Billion KRW | 8.4% |
| 2021 Q1 | 221.72 Billion KRW | 5.44% |
| 2021 Q4 | 227.95 Billion KRW | -0.63% |
| 2020 Q4 | 210.29 Billion KRW | 1.9% |
| 2020 FY | 210.29 Billion KRW | 6.58% |
| 2020 Q1 | 195.95 Billion KRW | -0.69% |
| 2020 Q3 | 206.37 Billion KRW | -3.57% |
| 2020 Q2 | 214 Billion KRW | 9.21% |
| 2019 Q2 | 163.29 Billion KRW | 10.47% |
| 2019 FY | 197.31 Billion KRW | 56.69% |
| 2019 Q4 | 197.31 Billion KRW | 6.32% |
| 2019 Q3 | 185.58 Billion KRW | 13.65% |
| 2019 Q1 | 147.81 Billion KRW | 17.38% |
| 2018 Q1 | 139.61 Billion KRW | -9.45% |
| 2018 Q4 | 125.92 Billion KRW | 8.98% |
| 2018 Q3 | 115.54 Billion KRW | -19.28% |
| 2018 FY | 125.92 Billion KRW | -18.33% |
| 2018 Q2 | 143.14 Billion KRW | 2.53% |
| 2017 Q2 | 165.32 Billion KRW | 3.27% |
| 2017 Q3 | 173.49 Billion KRW | 4.94% |
| 2017 Q4 | 154.19 Billion KRW | -11.13% |
| 2017 FY | 154.19 Billion KRW | -1.01% |
| 2017 Q1 | 160.09 Billion KRW | 2.78% |
| 2016 Q1 | 97.79 Billion KRW | 18.6% |
| 2016 Q3 | 110.52 Billion KRW | 3.49% |
| 2016 Q4 | 155.77 Billion KRW | 40.94% |
| 2016 FY | 155.77 Billion KRW | 88.91% |
| 2016 Q2 | 106.8 Billion KRW | 9.21% |
| 2015 FY | 82.45 Billion KRW | -0.15% |
| 2015 Q4 | 82.45 Billion KRW | 0.0% |
| 2014 Q1 | 105.28 Billion KRW | 93.33% |
| 2014 FY | 82.58 Billion KRW | 51.64% |
| 2014 Q2 | 78.44 Billion KRW | -25.49% |
| 2014 Q3 | 77.58 Billion KRW | -1.11% |
| 2013 Q1 | 42.44 Billion KRW | 3.17% |
| 2013 Q3 | 56.62 Billion KRW | -0.71% |
| 2013 Q4 | 54.45 Billion KRW | -3.82% |
| 2013 FY | 54.45 Billion KRW | 32.38% |
| 2013 Q2 | 57.02 Billion KRW | 34.36% |
| 2012 Q4 | 41.13 Billion KRW | 0.0% |
| 2012 FY | 41.13 Billion KRW | 3055.27% |
| 2012 Q1 | -1.16 Billion KRW | 0.0% |
| 2011 FY | -1.39 Billion KRW | -109.24% |
| 2011 Q3 | 6.93 Billion KRW | 17.14% |
| 2011 Q2 | 5.91 Billion KRW | 4342.26% |
| 2011 Q1 | -139.49 Million KRW | -100.93% |
| 2010 Q4 | 15.06 Billion KRW | -38.81% |
| 2010 FY | 15.06 Billion KRW | 25.72% |
| 2010 Q2 | 18.01 Billion KRW | 287.2% |
| 2010 Q3 | 24.62 Billion KRW | 36.7% |
| 2010 Q1 | 4.65 Billion KRW | -61.18% |
| 2009 Q3 | 2.51 Billion KRW | -76.22% |
| 2009 Q2 | 10.56 Billion KRW | 11.27% |
| 2009 Q4 | 11.98 Billion KRW | 376.84% |
| 2009 Q1 | 9.49 Billion KRW | -43.58% |
| 2009 FY | 11.98 Billion KRW | -28.81% |
| 2008 Q2 | 10.85 Billion KRW | 507.22% |
| 2008 Q1 | -2.66 Billion KRW | 85.4% |
| 2008 Q3 | 8.71 Billion KRW | -19.73% |
| 2008 FY | 16.83 Billion KRW | 192.17% |
| 2008 Q4 | 16.83 Billion KRW | 93.1% |
| 2007 Q2 | -3.99 Billion KRW | 65.99% |
| 2007 Q1 | -11.73 Billion KRW | 0.0% |
| 2007 Q3 | -19.51 Billion KRW | -388.87% |
| 2007 FY | -18.26 Billion KRW | 0.0% |
| 2007 Q4 | -18.26 Billion KRW | 6.43% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 8.8 Billion KRW | -3120.258% |
| Dong-A Socio Holdings Co., Ltd. | 572.02 Billion KRW | 50.447% |
| Ildong Holdings Co., Ltd. | 310.87 Billion KRW | 8.819% |
| Kukje Pharma Co., Ltd. | 20.07 Billion KRW | -1312.18% |
| Yuhan Corporation | -69.18 Billion KRW | 509.698% |
| Dong-A ST Co., Ltd. | 193.95 Billion KRW | -46.148% |
| SAMSUNG PHARM. Co., LTD. | -3.68 Billion KRW | 7790.436% |
| Hanmi Pharm. Co., Ltd. | 517.88 Billion KRW | 45.267% |
| Hanall Biopharma Co.,Ltd | -32.43 Billion KRW | 974.001% |
| Ilyang Pharmaceutical Co.,Ltd | 75.67 Billion KRW | -274.571% |
| Dong Sung Bio Pharm.Co.,Ltd. | 36.83 Billion KRW | -669.478% |
| MYUNGMOON Pharm co.,Ltd | 82.52 Billion KRW | -243.498% |
| Hana Pharm Co., Ltd. | 25.1 Billion KRW | -1028.926% |
| Yuyu Pharma, Inc. | 8.8 Billion KRW | -3120.258% |
| Ilsung Pharmaceuticals Co., Ltd. | -159.84 Billion KRW | 277.329% |
| REYON Pharmaceutical Co., Ltd. | 200.94 Billion KRW | -41.06% |
| Aprogen pharmaceuticals,Inc. | 170.94 Billion KRW | -65.818% |
| JW Holdings Corporation | 480.68 Billion KRW | 41.031% |
| Ildong Pharmaceutical Co., Ltd. | 164.58 Billion KRW | -72.227% |
| Chong Kun Dang Pharmaceutical Corp. | 117.53 Million KRW | -241073.938% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | -83.619% |
| Shin Poong Pharm.Co.,Ltd. | 2.35 Billion KRW | -11955.159% |
| Hyundai Pharmaceutical Co., Ltd. | 23 Billion KRW | -1132.337% |
| Samil Pharmaceutical Co.,Ltd | 174.97 Billion KRW | -62.0% |
| Jeil Pharmaceutical Co.,Ltd | 51.97 Billion KRW | -445.372% |
| Yuyu Pharma, Inc. | 8.8 Billion KRW | -3120.258% |
| Kwang Dong Pharmaceutical Co., Ltd. | 158.29 Billion KRW | -79.066% |
| Daewoong pharmaceutical Co.,Ltd | 358.17 Billion KRW | 20.862% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | -83.619% |
| Yuhan Corporation | -69.18 Billion KRW | 509.698% |
| Jeil Pharma Holdings Inc | 135.99 Billion KRW | -108.436% |
| Yungjin Pharm. Co., Ltd. | 59.67 Billion KRW | -375.005% |
| Suheung Co., Ltd. | 429.14 Billion KRW | 33.949% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | -83.619% |
| Samjin Pharmaceuticals Co., Ltd. | 116.23 Billion KRW | -143.861% |
| Korea United Pharm Inc. | 16.42 Billion KRW | -1625.744% |
| CKD Bio Corp. | 143.29 Billion KRW | -97.811% |
| Daewon Pharmaceutical Co., Ltd. | 116.06 Billion KRW | -144.217% |
| Dongwha Pharm.Co.,Ltd | -24.06 Billion KRW | 1278.035% |
| Whan In Pharm Co.,Ltd. | -44.73 Billion KRW | 733.645% |
| Shin Poong Pharm.Co.,Ltd. | 2.35 Billion KRW | -11955.159% |
| Chong Kun Dang Holdings Corp. | 422.84 Billion KRW | 32.964% |
| Boryung Corporation | 187.72 Billion KRW | -50.993% |
| Bukwang Pharmaceutical Co., Ltd. | -71.84 Billion KRW | 494.564% |
| Ilyang Pharmaceutical Co.,Ltd | 75.67 Billion KRW | -274.571% |
| JW Lifescience Corporation | 26.09 Billion KRW | -986.422% |